

Haematologica
HAEMATOL/2018/200220
Version 4

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors

Georgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, Gareth Gerrard, Edward Curry, Richard Szydlo, Mary Alikian, Hui En Foong, Zacharoula Nikolakopoulou, Sandra Loaiza, Jamshid S. Khorashad, Dragana Milojkovic, Danilo Perrotti, Robert Peter Gale, Letizia Foroni, and Jane F. Apperley

Disclosures: Robert Peter Gale is a part-time employee of Celgene Corp

Contributions: GN, JFA, LF, GG designed the study; GN, AB, HEF performed experiments; JFA, DM, AB, SC, SL, JSK collected samples; GN, EC, GG, MA performed the bioinformatics analysis of sequencing data; GN, RS, JFA, LF, SC interpreted the data and performed statistical analyses; GN, JFA, LF wrote the paper; RPG, DP, GG, ZN edited the paper.